Crizotinib and lorlatinib have been used in ALK-positive lung cancer (23, 24) and have shown efficacy in ALK-positive IMT at other sites, whereas ALK fusion-negative patients do not respond to these drugs (25). Here, ALK is linked to lung carcinoma.